Intraoperative Implementation of the Hypotension Probability Indicator (HYPE)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03376347 |
Recruitment Status :
Completed
First Posted : December 18, 2017
Last Update Posted : January 13, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Intraoperative Hypotension | Device: FlotracIQ with HPI algorithm | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 100 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Participant) |
Primary Purpose: | Treatment |
Official Title: | HYPE Trial. Intraoperative Implementation of the Hypotension Probability Indicator (HPI) Algorithm: a Pilot Randomized Controlled Clinical Trial |
Actual Study Start Date : | November 8, 2017 |
Actual Primary Completion Date : | March 20, 2019 |
Actual Study Completion Date : | March 20, 2019 |

Arm | Intervention/treatment |
---|---|
No Intervention: Conventional arm
Institutional Standard of Care with intention to keep MAP> 65 mmHg. The FlotracIQ will be connected, but fully covered.
|
|
Active Comparator: Treatment arm
FlotracIQ with HPI algorithm.
|
Device: FlotracIQ with HPI algorithm
FlotracIQ with hypotension probability indicator (HPI) algorithm connected to arterial line. The treating anesthetist is provided with guidance by means of a flowchart suggesting when to treat and what. Timing of treatment and choice of treatment is then left to the discretion of the attending physician. |
- TWA hypotension (measured with FlotracIQ) [ Time Frame: intraoperative, starting 15 minutes after induction ]Time weighted average spent in hypotension, defined as MAP <65mmHg for ≥1min
- Incidence of hypotension (measured with FlotracIQ) [ Time Frame: intraoperative, starting 15 minutes after induction ]Incidence of hypotension, defined as MAP <65mmHg for ≥1min
- Time spent in hypotension (measured with FlotracIQ) [ Time Frame: intraoperative, starting 15 minutes after induction ]Time spent in hypotension, in minutes, defined as MAP <65mmHg for ≥1min
- TWA hypertension (measured with FlotracIQ) [ Time Frame: intraoperative, starting 15 minutes after induction ]Time weighted average spent in hypertension, defined as MAP >100 mmHg for ≥1min
- Percentage of time in hypertension (measured with FlotracIQ) [ Time Frame: intraoperative, starting 15 minutes after induction ]Percentage of time in hypertension, defined as MAP >100 mmHg for ≥1min
- Incidence of hypertension (measured with FlotracIQ) [ Time Frame: intraoperative, starting 15 minutes after induction ]Incidence of hypertension, defined as MAP >100 mmHg for ≥1min.
- Treatment choice (CRF, EPD) [ Time Frame: intraoperative, starting 15 minutes after induction ]Medication used to prevent/treat hypotension. A study member is present at the OR to make notes
- Treatment dose (CRF, EPD) [ Time Frame: intraoperative, starting 15 minutes after induction ]Dose of medication used to prevent/treat hypotension. A study member is present at the OR to make notes
- Time to treatment (CRF) [ Time Frame: intraoperative, starting 15 minutes after induction ]time to treatment of hypotension, defined as MAP <65mmHg for ≥1min. A study member is present at the OR to make notes
- Diagnostic guidance protocol deviations (CRF) [ Time Frame: intraoperative, starting 15 minutes after induction ]Diagnostic guidance protocol deviations, a study member is present at the OR to make notes of any protocol deviations.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Aged 18 years or older
- Planned for elective non-cardiac non-day surgery with an expected duration of more than 2 hours
- Planned to receive general anaesthesia
- Planned to receive an arterial line during surgery
- Aim for MAP of 65 mmHg during surgery
- Being able to give written informed consent prior to surgery
Exclusion Criteria:
- Aim for MAP other than 65 mmHg at discretion treating physician
- Significant hypotension before surgery defined as a MAP <65
- Right- or left sided cardiac failure (e.g. LVEF<35%)
- Known cardiac shunts (significant)
- Known aortic stenosis (severe)
- Severe cardiac arrhythmias including atrial fibrillation
- Requiring dialysis
- Liver surgery
- Vascular surgery with clamping of the aorta
- Perioperative Goal Directed Therapy (PGDT) protocol

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03376347
Netherlands | |
Academic Medical Center Amsterdam | |
Amsterdam, Netherlands |
Principal Investigator: | M.W. Hollmann, MD, PhD | Academic Medical Center (AMC), Amsterdam |
Responsible Party: | D.P.Veelo, Principal Investigator, Medical Doctor, PhD, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
ClinicalTrials.gov Identifier: | NCT03376347 |
Other Study ID Numbers: |
NL 6211501817 |
First Posted: | December 18, 2017 Key Record Dates |
Last Update Posted: | January 13, 2020 |
Last Verified: | January 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
intraoperative hypotension Hypotension Probability Index HPI |
Hypotension Vascular Diseases Cardiovascular Diseases |